Pharvaris (PHVS) Income from Continuing Operations (2020 - 2026)
Pharvaris' (PHVS) quarterly Income from Continuing Operations came in at 45254539.73 in Q1 2026, up 5.93% YoY from 42720270.06 in Q1 2025, and up 10.45% on a QoQ basis from 50534633.91 in Q4 2025.
Pharvaris (PHVS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Income from Continuing Operations data on file, last reported at 45254539.73 in Q1 2026.
- Quarterly Income from Continuing Operations rose 5.93% year-over-year to 45254539.73 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 190651929.03 (down 19.33% YoY) and the FY2025 annual result came in at 194015239.2, down 37.29% from the prior year.
- Income from Continuing Operations improved to 45254539.73 in Q1 2026, from 50534633.91 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 7617572.58 in Q2 2022 to a low of 51023221.04 in Q2 2025.
- A 5-year average of 33580127.66 and a median of 34496988.71 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 58.38% — and 2023, when it sank 210.34%.
- Tracing PHVS's Income from Continuing Operations over 5 years: stood at 41450118.2 in 2022, then grew by 10.56% to 37073171.89 in 2023, then gained by 6.95% to 34496988.71 in 2024, then slumped by 46.49% to 50534633.91 in 2025, then gained by 10.45% to 45254539.73 in 2026.
- The last three Income from Continuing Operations figures came in at 45254539.73 (Q1 2026), 50534633.91 (Q4 2025), and 43839534.36 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | -55.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.57 Mn |
| Mar 31, 2026 | -45.25 Mn |
| Dec 31, 2025 | -50.53 Mn |
| Sep 30, 2025 | -43.84 Mn |
| Jun 30, 2025 | -51.02 Mn |
| Mar 31, 2025 | -48.11 Mn |
| Dec 31, 2024 | -34.50 Mn |
| Sep 30, 2024 | -45.30 Mn |
| Jun 30, 2024 | -31.86 Mn |
| Mar 31, 2024 | -29.82 Mn |
| Dec 31, 2023 | -37.07 Mn |
| Sep 30, 2023 | -25.37 Mn |
| Jun 30, 2023 | -23.64 Mn |
| Mar 31, 2023 | -24.16 Mn |
| Dec 31, 2022 | -41.45 Mn |
| Sep 30, 2022 | -13.41 Mn |
| Jun 30, 2022 | -7.62 Mn |
| Mar 31, 2022 | -17.90 Mn |
| Dec 31, 2021 | 34,559.40 Bn |
| Sep 30, 2021 | -10.62 Mn |